YS-363 is a potent, selective, and orally active EGFR inhibitor, with IC50s of 0.96 nM and 0.67 nM for wild-type and L858R mutant forms of EGFR, respectively. YS-363 can induce G0/G1 cell cycle arrest and apoptosis.
References:
[1]. He P, et, al. Discovery of YS-363 as a highly potent, selective, and orally efficacious EGFR inhibitor. Biomed Pharmacother. 2023 Nov:167:115491.